Samsung Bioepis and Teva Signed Biosimilar Pact
The companies partnered to develop and commercialize six potential biosimilar treatments in key global markets.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you believe increasing the availability of biosimilar medicines will help lower overall healthcare costs?
Samsung Bioepis and Teva Pharmaceutical Industries have entered into a licensing agreement to develop, manufacture, and commercialize six biosimilar candidates. The deal encompasses two confirmed assets, SB41 and SB44, which reference the medications Fasenra and Ilaris, respectively.
Why it matters
The partnership aims to accelerate patient access to biosimilar medicines by combining Samsung Bioepis’s development and manufacturing capabilities with Teva’s established commercial networks. This expansion builds upon the pair's existing work on products like EPYSQLI and OPUVIZ.
The agreement includes two confirmed candidates, SB41 and SB44, alongside an option for four additional assets. These biosimilars—biological medical products highly similar to an existing FDA-approved reference product—will be developed by Samsung Bioepis with Teva handling sales.
The players
Samsung Bioepis
A joint venture focused on the development, clinical trial management, and large-scale manufacturing of biosimilar pharmaceuticals.
Teva Pharmaceutical Industries
A global pharmaceutical firm with an extensive commercial infrastructure specializing in generic and specialty medicines.
The details
Under this partnership, Samsung Bioepis manages the end-to-end development, regulatory registration, and manufacturing process for the drugs. Teva acts as the commercial entity responsible for bringing these therapies to market across the United States, Europe, and Canada. The candidates SB41 and SB44 target the reference biologics Fasenra (benralizumab), a monoclonal antibody for asthma, and Ilaris (canakinumab), used for certain inflammatory conditions.
Timeline
October 1, 2026: Samsung Bioepis and Teva announced the new partnership agreement.
The Tech Race
The expansion follows the successful precedent established by the EPYSQLI biosimilar commercialization partnership. This agreement significantly scales the previous collaborative framework by adding six potential candidates to the existing portfolio.
Patients in the United States, Europe, and Canada may eventually see expanded options for biosimilar therapies as these candidates progress through development. Implementation remains subject to regulatory approval, as the companies have not provided specific rollout dates for the new candidates.
The takeaway
The alliance creates a path for six new biosimilar assets to move from development to global markets. Industry observers should watch for further clinical updates or regulatory filings for SB41 and SB44 as the primary indicators of this agreement's progress.
Further reading
For more on how companies are scaling their pipelines, browse the latest research in Biotech.
Live Poll
Do you believe increasing the availability of biosimilar medicines will help lower overall healthcare costs?
